Multifaceted regulation and functions of YAP/TAZ in tumors (Review)
- Authors:
- Huirong Liu
- Suya Du
- Tiantian Lei
- Hailian Wang
- Xia He
- Rongsheng Tong
- Yi Wang
-
Affiliations: Center of Organ Transplantation, Sichuan Academy of Medical Science and Sichuan Provincial People's Hospital, Chengdu, Sichuan 610072, P.R. China, School of Medicine, University of Electronic Science and Technology of China Chengdu, Sichuan 610054, P.R. China, Personalized Drug Therapy Key Laboratory of Sichuan Province, Department of Pharmacy, Sichuan Academy of Medical Science and Sichuan Provincial People's Hospital, Chengdu, Sichuan 610072, P.R. China - Published online on: May 8, 2018 https://doi.org/10.3892/or.2018.6423
- Pages: 16-28
-
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
 |
 |
 |
|
Santucci M, Vignudelli T, Ferrari S, Mor M, Scalvini L, Bolognesi ML, Uliassi E and Costi MP: The Hippo pathway and YAP/TAZ-TEAD protein-protein interaction as targets for regenerative medicine and cancer treatment. J Med Chem. 58:4857–4873. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao B, Li L, Lei Q and Guan KL: The Hippo-YAP pathway in organ size control and tumorigenesis: An updated version. Genes Dev. 24:862–874. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao B, Tumaneng K and Guan KL: The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal. Nat Cell Biol. 13:877–883. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, Xie J, Ikenoue T, Yu J, Li L, et al: Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 21:2747–2761. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Lei QY, Zhang H, Zhao B, Zha ZY, Bai F, Pei XH, Zhao S, Xiong Y and Guan KL: TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Mol Cell Biol. 28:2426–2436. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Cai J, Zhang N, Zheng Y, de Wilde RF, Maitra A and Pan D: The Hippo signaling pathway restricts the oncogenic potential of an intestinal regeneration program. Genes Dev. 24:2383–2388. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Hong W and Guan KL: The YAP and TAZ transcription co-activators: Key downstream effectors of the mammalian Hippo pathway. Semin Cell Dev Biol. 23:785–793. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Barry ER, Morikawa T, Butler BL, Shrestha K, de la Rosa R, Yan KS, Fuchs CS, Magness ST, Smits R, Ogino S, et al: Restriction of intestinal stem cell expansion and the regenerative response by YAP. Nature. 493:106–110. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Ma Y, Yang Y, Wang F, Wei Q and Qin H: Hippo-YAP signaling pathway: A new paradigm for cancer therapy. Int J Cancer. 137:2275–2286. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Mo JS, Park HW and Guan KL: The Hippo signaling pathway in stem cell biology and cancer. EMBO Rep. 15:642–656. 2014.PubMed/NCBI | |
|
Pan D: The hippo signaling pathway in development and cancer. Dev Cell. 19:491–505. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Wang L, Shi S, Guo Z, Zhang X, Han S, Yang A, Wen W and Zhu Q: Overexpression of YAP and TAZ is an independent predictor of prognosis in colorectal cancer and related to the proliferation and metastasis of colon cancer cells. PLoS One. 8:e655392013. View Article : Google Scholar : PubMed/NCBI | |
|
Halder G and Johnson RL: Hippo signaling: Growth control and beyond. Development. 138:9–22. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Moroishi T, Hansen CG and Guan KL: The emerging roles of YAP and TAZ in cancer. Nat Rev Cancer. 15:73–79. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Piccolo S, Dupont S and Cordenonsi M: The biology of YAP/TAZ: Hippo signaling and beyond. Physiol Rev. 94:1287–1312. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Moroishi T, Park HW, Qin B, Chen Q, Meng Z, Plouffe SW, Taniguchi K, Yu FX, Karin M, Pan D, et al: A YAP/TAZ-induced feedback mechanism regulates Hippo pathway homeostasis. Genes Dev. 29:1271–1284. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Wang L, Chen Z, Wang Y, Chang D, Su L, Guo Y and Liu C: TR1 promotes cell proliferation and inhibits apoptosis through cyclin A and CTGF regulation in non-small cell lung cancer. Tumour Biol. 35:463–468. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Nishioka N, Inoue K, Adachi K, Kiyonari H, Ota M, Ralston A, Yabuta N, Hirahara S, Stephenson RO, Ogonuki N, et al: The Hippo signaling pathway components Lats and Yap pattern Tead4 activity to distinguish mouse trophectoderm from inner cell mass. Dev Cell. 16:398–410. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Xin M, Kim Y, Sutherland LB, Murakami M, Qi X, McAnally J, Porrello ER, Mahmoud AI, Tan W, Shelton JM, et al: Hippo pathway effector Yap promotes cardiac regeneration. Proc Natl Acad Sci USA. 110:13839–13844. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Zaidi SK, Sullivan AJ, Medina R, Ito Y, van Wijnen AJ, Stein JL, Lian JB and Stein GS: Tyrosine phosphorylation controls Runx2-mediated subnuclear targeting of YAP to repress transcription. EMBO J. 23:790–799. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou Z, Hu T, Xu Z, Lin Z, Zhang Z, Feng T, Zhu L, Rong Y, Shen H, Luk JM, et al: Targeting Hippo pathway by specific interruption of YAP-TEAD interaction using cyclic YAP-like peptides. FASEB J. 29:724–732. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Varelas X: The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease. Development. 141:1614–1626. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Han SX, Bai E, Jin GH, He CC, Guo XJ, Wang LJ, Li M, Ying X and Zhu Q: Expression and clinical significance of YAP, TAZ, and AREG in hepatocellular carcinoma. J Immunol Res. 2014:2613652014. View Article : Google Scholar : PubMed/NCBI | |
|
Sudol M, Bork P, Einbond A, Kastury K, Druck T, Negrini M, Huebner K and Lehman D: Characterization of the mammalian YAP (Yes-associated protein) gene and its role in defining a novel protein module, the WW domain. J Biol Chem. 270:14733–14741. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Morin-Kensicki EM, Boone BN, Howell M, Stonebraker JR, Teed J, Alb JG, Magnuson TR, O'Neal W and Milgram SL: Defects in yolk sac vasculogenesis, chorioallantoic fusion, and embryonic axis elongation in mice with targeted disruption of Yap65. Mol Cell Biol. 26:77–87. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Muramatsu T, Imoto I, Matsui T, Kozaki K, Haruki S, Sudol M, Shimada Y, Tsuda H, Kawano T and Inazawa J: YAP is a candidate oncogene for esophageal squamous cell carcinoma. Carcinogenesis. 32:389–398. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Gaffney CJ, Oka T, Mazack V, Hilman D, Gat U, Muramatsu T, Inazawa J, Golden A, Carey DJ, Farooq A, et al: Identification, basic characterization and evolutionary analysis of differentially spliced mRNA isoforms of human YAP1 gene. Gene. 509:215–222. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Yu FX, Luo J, Mo JS, Liu G, Kim YC, Meng Z, Zhao L, Peyman G, Ouyang H, Jiang W, et al: Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP. Cancer Cell. 25:822–830. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Hall CA, Wang R, Miao J, Oliva E, Shen X, Wheeler T, Hilsenbeck SG, Orsulic S and Goode S: Hippo pathway effector Yap is an ovarian cancer oncogene. Cancer Res. 70:8517–8525. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Sudol M: Yes-associated protein (YAP65) is a proline-rich phosphoprotein that binds to the SH3 domain of the Yes proto-oncogene product. Oncogene. 9:2145–2152. 1994.PubMed/NCBI | |
|
Kanai F, Marignani PA, Sarbassova D, Yagi R, Hall RA, Donowitz M, Hisaminato A, Fujiwara T, Ito Y, Cantley LC, et al: TAZ: A novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. EMBO J. 19:6778–6791. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Li PD, Wang XJ, Shan Q, Wu YH and Wang Z: Evaluation of TAZ expression and its effect on tumor invasion and metastasis in human glioma. Asian Pac J Trop Med. 7:757–760. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Nagaraj R, Gururaja-Rao S, Jones KT, Slattery M, Negre N, Braas D, Christofk H, White KP, Mann R and Banerjee U: Control of mitochondrial structure and function by the Yorkie/YAP oncogenic pathway. Genes Dev. 26:2027–2037. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Guo L and Teng L: YAP/TAZ for cancer therapy: Opportunities and challenges (Review). Int J Oncol. 46:1444–1452. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Oka T and Sudol M: Nuclear localization and pro-apoptotic signaling of YAP2 require intact PDZ-binding motif. Genes Cells. 14:607–615. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Sawada A, Kiyonari H, Ukita K, Nishioka N, Imuta Y and Sasaki H: Redundant roles of Tead1 and Tead2 in notochord development and the regulation of cell proliferation and survival. Mol Cell Biol. 28:3177–3189. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Hiemer SE, Zhang L, Kartha VK, Packer TS, Almershed M, Noonan V, Kukuruzinska M, Bais MV, Monti S and Varelas X: A YAP/TAZ-Regulated Molecular Signature Is Associated with Oral Squamous Cell Carcinoma. Mol Cancer Res. 13:957–968. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Chan SW, Lim CJ, Chong YF, Pobbati AV, Huang C and Hong W: Hippo pathway-independent restriction of TAZ and YAP by angiomotin. J Biol Chem. 286:7018–7026. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Liu C, Huang W and Lei Q: Regulation and function of the TAZ transcription co-activator. Int J Biochem Mol Biol. 2:247–256. 2011.PubMed/NCBI | |
|
Yue G, Sun X, Gimenez-Capitan A, Shen J, Yu L, Teixido C, Guan W, Rosell R, Liu B and Wei J: TAZ is highly expressed in gastric signet ring cell carcinoma. BioMed Res Int. 2014:3930642014. View Article : Google Scholar : PubMed/NCBI | |
|
Aqeilan RI, Donati V, Palamarchuk A, Trapasso F, Kaou M, Pekarsky Y, Sudol M and Croce CM: WW domain-containing proteins, WWOX and YAP, compete for interaction with ErbB-4 and modulate its transcriptional function. Cancer Res. 65:6764–6772. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Donzelli S, Strano S and Blandino G: YAP and p73: A matter of mutual specificity in tumor suppressionThe Hippo Signaling Pathway and Cancer. Springer; New York: pp. 147–172. 2013, View Article : Google Scholar | |
|
Azzolin L, Zanconato F, Bresolin S, Forcato M, Basso G, Bicciato S, Cordenonsi M and Piccolo S: Role of TAZ as mediator of Wnt signaling. Cell. 151:1443–1456. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Low BC, Pan CQ, Shivashankar GV, Bershadsky A, Sudol M and Sheetz M: YAP/TAZ as mechanosensors and mechanotransducers in regulating organ size and tumor growth. FEBS Lett. 588:2663–2670. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Acerbi I, Cassereau L, Dean I, Shi Q, Au A, Park C, Chen YY, Liphardt J, Hwang ES and Weaver VM: Human breast cancer invasion and aggression correlates with ECM stiffening and immune cell infiltration. Integr Biol. 7:1120–1134. 2015. View Article : Google Scholar | |
|
Calvo F, Ege N, Grande-Garcia A, Hooper S, Jenkins RP, Chaudhry SI, Harrington K, Williamson P, Moeendarbary E, Charras G, et al: Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat Cell Biol. 15:637–646. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Halder G, Dupont S and Piccolo S: Transduction of mechanical and cytoskeletal cues by YAP and TAZ. Nat Rev Mol Cell Biol. 13:591–600. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Aragona M, Panciera T, Manfrin A, Giulitti S, Michielin F, Elvassore N, Dupont S and Piccolo S: A mechanical checkpoint controls multicellular growth through YAP/TAZ regulation by actin-processing factors. Cell. 154:1047–1059. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Gibson WT and Gibson MC: Cell topology, geometry, and morphogenesis in proliferating epithelia. Curr Top Dev Biol. 89:87–114. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Vogel V and Sheetz M: Local force and geometry sensing regulate cell functions. Nat Rev Mol Cell Biol. 7:265–275. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Furukawa KT, Yamashita K, Sakurai N and Ohno S: The epithelial circumferential actin belt regulates YAP/TAZ through nucleocytoplasmic shuttling of merlin. Cell Reports. 20:1435–1447. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Matsui Y and Lai ZC: Mutual regulation between Hippo signaling and actin cytoskeleton. Protein Cell. 4:904–910. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao B, Li L, Wang L, Wang CY, Yu J and Guan KL: Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. Genes Dev. 26:54–68. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Wada K, Itoga K, Okano T, Yonemura S and Sasaki H: Hippo pathway regulation by cell morphology and stress fibers. Development. 138:3907–3914. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Sansores-Garcia L, Bossuyt W, Wada K, Yonemura S, Tao C, Sasaki H and Halder G: Modulating F-actin organization induces organ growth by affecting the Hippo pathway. EMBO J. 30:2325–2335. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Talele NP, Fradette J, Davies JE, Kapus A and Hinz B: Expression of α-smooth muscle actin determines the fate of mesenchymal stromal cells. Stem Cell Reports. 4:1016–1030. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Miyabara S, Yuda Y, Kasashima Y, Kuwano A and Arai K: Regulation of Tenomodulin Expression Via Wnt/β-catenin Signaling in Equine Bone Marrow-derived Mesenchymal Stem Cells. J Equine Sci. 25:7–13. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Lustig B and Behrens J: The Wnt signaling pathway and its role in tumor development. J Cancer Res Clin Oncol. 129:199–221. 2003.PubMed/NCBI | |
|
Yu FX, Zhao B and Guan KL: Hippo pathway in organ size control, tissue homeostasis, and cancer. Cell. 163:811–828. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Konsavage WM Jr and Yochum GS: Intersection of Hippo/YAP and Wnt/β-catenin signaling pathways. Acta Biochim Biophys Sin (Shanghai). 45:71–79. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Konsavage WM Jr, Kyler SL, Rennoll SA, Jin G and Yochum GS: Wnt/β-catenin signaling regulates Yes-associated protein (YAP) gene expression in colorectal carcinoma cells. J Biol Chem. 287:11730–11739. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Huang W, Lv X, Liu C, Zha Z, Zhang H, Jiang Y, Xiong Y, Lei QY and Guan KL: The N-terminal phosphodegron targets TAZ/WWTR1 protein for SCFβ-TrCP-dependent degradation in response to phosphatidylinositol 3-kinase inhibition. J Biol Chem. 287:26245–26253. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Nishita M, Endo M and Minami Y: Regulation of cellular responses by non-canonical Wnt signaling. Clin Calcium. 23:809–815. 2013.(In Japanese). PubMed/NCBI | |
|
Korswagen HC: Canonical and non-canonical Wnt signaling pathways in Caenorhabditis elegans: Variations on a common signaling theme. BioEssays. 24:801–810. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Park HW, Kim YC, Yu B, Moroishi T, Mo JS, Plouffe SW, Meng Z, Lin KC, Yu FX, Alexander CM, et al: Alternative Wnt Signaling Activates YAP/TAZ. Cell. 162:780–794. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Azzolin L, Panciera T, Soligo S, Enzo E, Bicciato S, Dupont S, Bresolin S, Frasson C, Basso G, Guzzardo V, et al: YAP/TAZ incorporation in the β-catenin destruction complex orchestrates the Wnt response. Cell. 158:157–170. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Varelas X, Miller BW, Sopko R, Song S, Gregorieff A, Fellouse FA, Sakuma R, Pawson T, Hunziker W, McNeill H, et al: The Hippo pathway regulates Wnt/beta-catenin signaling. Dev Cell. 18:579–591. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Imajo M, Miyatake K, Iimura A, Miyamoto A and Nishida E: A molecular mechanism that links Hippo signalling to the inhibition of Wnt/β-catenin signalling. EMBO J. 31:1109–1122. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Lappano R and Maggiolini M: G protein-coupled receptors: Novel targets for drug discovery in cancer. Nat Rev Drug Discov. 10:47–60. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Prickett TD, Wei X, Cardenas-Navia I, Teer JK, Lin JC, Walia V, Gartner J, Jiang J, Cherukuri PF, Molinolo A, et al: Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma. Nat Genet. 43:1119–1126. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Paschke R and Ludgate M: The thyrotropin receptor in thyroid diseases. N Engl J Med. 337:1675–1681. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Hernández NA, Correa E, Avila EP, Vela TA and Pérez VM: PAR1 is selectively over expressed in high grade breast cancer patients: A cohort study. J Transl Med. 7:472009. View Article : Google Scholar : PubMed/NCBI | |
|
Guo X and Zhao B: Integration of mechanical and chemical signals by YAP and TAZ transcription coactivators. Cell Biosci. 3:332013. View Article : Google Scholar : PubMed/NCBI | |
|
Miller E, Yang J, DeRan M, Wu C, Su AI, Bonamy GMC, Liu J, Peters EC and Wu X: Identification of serum-derived sphingosine-1-phosphate as a small molecule regulator of YAP. Chem Biol. 19:955–962. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Yu FX, Zhao B, Panupinthu N, Jewell JL, Lian I, Wang LH, Zhao J, Yuan H, Tumaneng K, Li H, et al: Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell. 150:780–791. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Waldron RT, Innamorati G, Torres-Marquez ME, Sinnett-Smith J, Rozengurt E and RT W: Differential PKC-dependent and -independent PKD activation by G protein α subunits of the Gq family: Selective stimulation of PKD Ser748 autophosphorylation by Gαq. Cell Signal. 24:914–921. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Wang J, Sinnett-Smith J, Stevens JV, Young SH and Rozengurt E: Biphasic regulation of Yes-associated protein (YAP) cellular localization, phosphorylation, and activity by G protein-coupled receptor agonists in intestinal epithelial cells: A novel role for protein kinase D (PKD). J Biol Chem. 291:17988–18005. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Hao F, Xu Q, Zhao Y, Stevens JV, Young SH, Sinnett-Smith J and Rozengurt E: Insulin receptor and GPCR crosstalk stimulates YAP via PI3K and PKD in pancreatic cancer cells. Mol Cancer Res. 15:929–941. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Vigneron AM, Ludwig RL and Vousden KH: Cytoplasmic ASPP1 inhibits apoptosis through the control of YAP. Genes Dev. 24:2430–2439. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Hansen CG, Ng YL, Lam WL, Plouffe SW and Guan KL: The Hippo pathway effectors YAP and TAZ promote cell growth by modulating amino acid signaling to mTORC1. Cell Res. 25:1299–1313. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Kim M, Kim T, Johnson RL and Lim DS: Transcriptional co-repressor function of the hippo pathway transducers YAP and TAZ. Cell Reports. 11:270–282. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou X, Wang S, Wang Z, Feng X, Liu P, Lv XB, Li F, Yu FX, Sun Y, Yuan H, et al: Estrogen regulates Hippo signaling via GPER in breast cancer. J Clin Invest. 125:2123–2135. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao B, Ye X, Yu J, Li L, Li W, Li S, Yu J, Lin JD, Wang CY, Chinnaiyan AM, et al: TEAD mediates YAP-dependent gene induction and growth control. Genes Dev. 22:1962–1971. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Zanconato F, Forcato M, Battilana G, Azzolin L, Quaranta E, Bodega B, Rosato A, Bicciato S, Cordenonsi M and Piccolo S: Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth. Nat Cell Biol. 17:1218–1227. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Escoll M, Gargini R, Cuadrado A, Anton IM and Wandosell F: Mutant p53 oncogenic functions in cancer stem cells are regulated by WIP through YAP/TAZ. Oncogene. 36:3515–3527. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Cordenonsi M, Zanconato F, Azzolin L, Forcato M, Rosato A, Frasson C, Inui M, Montagner M, Parenti AR, Poletti A, et al: The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell. 147:759–772. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Hiemer SE, Szymaniak AD and Varelas X: The transcriptional regulators TAZ and YAP direct transforming growth factor β-induced tumorigenic phenotypes in breast cancer cells. J Biol Chem. 289:13461–13474. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Bhat KP, Salazar KL, Balasubramaniyan V, Wani K, Heathcock L, Hollingsworth F, James JD, Gumin J, Diefes KL, Kim SH, et al: The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes Dev. 25:2594–2609. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Lau AN, Curtis SJ, Fillmore CM, Rowbotham SP, Mohseni M, Wagner DE, Beede AM, Montoro DT, Sinkevicius KW, Walton ZE, et al: Tumor-propagating cells and Yap/Taz activity contribute to lung tumor progression and metastasis. EMBO J. 33:468–481. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Tsutsumi R, Masoudi M, Takahashi A, Fujii Y, Hayashi T, Kikuchi I, Satou Y, Taira M and Hatakeyama M: YAP and TAZ, Hippo signaling targets, act as a rheostat for nuclear SHP2 function. Dev Cell. 26:658–665. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Bae JS, Kim SM and Lee H: The Hippo signaling pathway provides novel anti-cancer drug targets. Oncotarget. 8:16084–16098. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Tao Y, Cai F, Shan L, Jiang H, Ma L and Yu Y: The Hippo signaling pathway: An emerging anti-cancer drug target. Discov Med. 24:7–18. 2017.PubMed/NCBI | |
|
Zanconato F, Battilana G, Cordenonsi M and Piccolo S: YAP/TAZ as therapeutic targets in cancer. Curr Opin Pharmacol. 29:26–33. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Enzo E, Santinon G, Pocaterra A, Aragona M, Bresolin S, Forcato M, Grifoni D, Pession A, Zanconato F, Guzzo G, et al: Aerobic glycolysis tunes YAP/TAZ transcriptional activity. EMBO J. 34:1349–1370. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Wong W: Keeping cells from getting Hippo-sized under energy stress. Sci Signal. 8:ec1082015. View Article : Google Scholar | |
|
Mo JS, Meng Z, Kim YC, Park HW, Hansen CG, Kim S, Lim DS and Guan KL: Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway. Nat Cell Biol. 17:500–510. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
DeRan M, Yang J, Shen CH, Peters EC, Fitamant J, Chan P, Hsieh M, Zhu S, Asara JM, Zheng B, et al: Energy stress regulates hippo-YAP signaling involving AMPK-mediated regulation of angiomotin-like 1 protein. Cell Reports. 9:495–503. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Santinon G, Pocaterra A and Dupont S: Control of YAP/TAZ activity by metabolic and nutrient-sensing pathways. Trends Cell Biol. 26:289–299. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Sorrentino G, Ruggeri N, Specchia V, Cordenonsi M, Mano M, Dupont S, Manfrin A, Ingallina E, Sommaggio R, Piazza S, et al: Metabolic control of YAP and TAZ by the mevalonate pathway. Nat Cell Biol. 16:357–366. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Nallet-Staub F, Marsaud V, Li L, Gilbert C, Dodier S, Bataille V, Sudol M, Herlyn M and Mauviel A: Pro-invasive activity of the Hippo pathway effectors YAP and TAZ in cutaneous melanoma. J Invest Dermatol. 134:123–132. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao B, Li L, Lu Q, Wang LH, Liu CY, Lei Q and Guan KL: Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. Genes Dev. 25:51–63. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Hsu YL, Hung JY, Chou SH, Huang MS, Tsai MJ, Lin YS, Chiang SY, Ho YW, Wu CY and Kuo PL: Angiomotin decreases lung cancer progression by sequestering oncogenic YAP/TAZ and decreasing Cyr61 expression. Oncogene. 34:4056–4068. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Pegoraro S, Ros G, Ciani Y, Sgarra R, Piazza S and Manfioletti G: A novel HMGA1-CCNE2-YAP axis regulates breast cancer aggressiveness. Oncotarget. 6:19087–19101. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Wilson KE, Li YW, Yang N, Shen H, Orillion AR and Zhang J: PTPN14 forms a complex with Kibra and LATS1 proteins and negatively regulates the YAP oncogenic function. J Biol Chem. 289:23693–23700. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Huang JM, Nagatomo I, Suzuki E, Mizuno T, Kumagai T, Berezov A, Zhang H, Karlan B, Greene MI and Wang Q: YAP modifies cancer cell sensitivity to EGFR and survivin inhibitors and is negatively regulated by the non-receptor type protein tyrosine phosphatase 14. Oncogene. 32:2220–2229. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Gao Y, Shi Q, Xu S, Du C, Liang L, Wu K, Wang K, Wang X, Chang LS, He D, et al: Curcumin promotes KLF5 proteasome degradation through downregulating YAP/TAZ in bladder cancer cells. Int J Mol Sci. 15:15173–15187. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Oku Y, Nishiya N, Shito T, Yamamoto R, Yamamoto Y, Oyama C and Uehara Y: Small molecules inhibiting the nuclear localization of YAP/TAZ for chemotherapeutics and chemosensitizers against breast cancers. FEBS Open Bio. 5:542–549. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Rosenbluh J, Nijhawan D, Cox AG, Li X, Neal JT, Schafer EJ, Zack TI, Wang X, Tsherniak A, Schinzel AC, et al: β-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell. 151:1457–1473. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Rao J and Li N: Microfilament actin remodeling as a potential target for cancer drug development. Curr Cancer Drug Targets. 4:345–354. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Morikawa Y, Zhang M, Heallen T, Leach J, Tao G, Xiao Y, Bai Y, Li W, Willerson JT and Martin JF: Actin cytoskeletal remodeling with protrusion formation is essential for heart regeneration in Hippo-deficient mice. Sci Signal. 8:ra412015. View Article : Google Scholar : PubMed/NCBI | |
|
Kim MH and Kim J, Hong H, Lee SH, Lee JK, Jung E and Kim J: Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP/TAZ activation. EMBO J. 35:462–478. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Ferrarelli LK: Actin against BRAF inhibitors. Sci Signal. 9:ec512016. View Article : Google Scholar | |
|
Wang P, Bai Y, Song B, Wang Y, Liu D, Lai Y, Bi X and Yuan Z: PP1A-mediated dephosphorylation positively regulates YAP2 activity. PLoS One. 6:e242882011. View Article : Google Scholar : PubMed/NCBI | |
|
Mao B, Hu F, Cheng J, Wang P, Xu M, Yuan F, Meng S, Wang Y, Yuan Z and Bi W: SIRT1 regulates YAP2-mediated cell proliferation and chemoresistance in hepatocellular carcinoma. Oncogene. 33:1468–1474. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Imanaka Y, Tsuchiya S, Sato F, Shimada Y, Shimizu K and Tsujimoto G: MicroRNA-141 confers resistance to cisplatin-induced apoptosis by targeting YAP1 in human esophageal squamous cell carcinoma. J Hum Genet. 56:270–276. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou Z, Hao Y, Liu N, Raptis L, Tsao MS and Yang X: TAZ is a novel oncogene in non-small cell lung cancer. Oncogene. 30:2181–2186. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Anastasiadou E, Jacob LS and Slack FJ: Non-coding RNA networks in cancer. Nat Rev Cancer. 18:5–18. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Esteller M: Non-coding RNAs in human disease. Nat Rev Genet. 12:861–874. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
He L and Hannon GJ: MicroRNAs: Small RNAs with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al: MicroRNA expression profiles classify human cancers. Nature. 435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Stefani G and Slack FJ: Small non-coding RNAs in animal development. Nat Rev Mol Cell Biol. 9:219–230. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Sassen S, Miska EA and Caldas C: MicroRNA: Implications for cancer. Virchows Arch. 452:1–10. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Kim HS, Lee KS, Bae HJ, Eun JW, Shen Q, Park SJ, Shin WC, Yang HD, Park M, Park WS, et al: MicroRNA-31 functions as a tumor suppressor by regulating cell cycle and epithelial-mesenchymal transition regulatory proteins in liver cancer. Oncotarget. 6:8089–8102. 2015.PubMed/NCBI | |
|
Lin S and Gregory RI: MicroRNA biogenesis pathways in cancer. Nat Rev Cancer. 15:321–333. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Nishikawa R, Goto Y, Kojima S, Enokida H, Chiyomaru T, Kinoshita T, Sakamoto S, Fuse M, Nakagawa M, Naya Y, et al: Tumor-suppressive microRNA-29s inhibit cancer cell migration and invasion via targeting LAMC1 in prostate cancer. Int J Oncol. 45:401–410. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Nishikawa R, Goto Y, Sakamoto S, Chiyomaru T, Enokida H, Kojima S, Kinoshita T, Yamamoto N, Nakagawa M, Naya Y, et al: Tumor-suppressive microRNA-218 inhibits cancer cell migration and invasion via targeting of LASP1 in prostate cancer. Cancer Sci. 105:802–811. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Ouyang H, Gore J, Deitz S and Korc M: microRNA-10b enhances pancreatic cancer cell invasion by suppressing TIP30 expression and promoting EGF and TGF-β actions. Oncogene. 33:4664–4674. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Cirilo PDR, de Sousa Andrade LN, Corrêa BRS, Qiao M, Furuya TK, Chammas R and Penalva LOF: MicroRNA-195 acts as an anti-proliferative miRNA in human melanoma cells by targeting Prohibitin 1. BMC Cancer. 17:7502017. View Article : Google Scholar : PubMed/NCBI | |
|
Halytskiy V: Shifts in miRNA expression pattern can lead to the loss of contact inhibition in breast cancer cells. Eur J Cancer. 57 Suppl 2:S1162016. | |
|
Liu P, Zhang H, Liang X, Ma H, Luan F, Wang B, Bai F, Gao L and Ma C: HBV preS2 promotes the expression of TAZ via miRNA-338-3p to enhance the tumorigenesis of hepatocellular carcinoma. Oncotarget. 6:29048–29059. 2015.PubMed/NCBI | |
|
Higashi T, Hayashi H, Ishimoto T, Takeyama H, Kaida T, Arima K, Taki K, Sakamoto K, Kuroki H, Okabe H, et al: miR-9-3p plays a tumour-suppressor role by targeting TAZ (WWTR1) in hepatocellular carcinoma cells. Br J Cancer. 113:252–258. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Liu AM, Poon RT and Luk JM: MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties. Biochem Biophys Res Commun. 394:623–627. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Tan G, Cao X, Dai Q, Zhang B, Huang J, Xiong S, Zhang Y, Chen W, Yang J and Li H: A novel role for microRNA-129-5p in inhibiting ovarian cancer cell proliferation and survival via direct suppression of transcriptional co-activators YAP and TAZ. Oncotarget. 6:8676–8686. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Hua K, Yang W, Song H, Song J, Wei C, Li D and Fang L: Up-regulation of miR-506 inhibits cell growth and disrupt the cell cycle by targeting YAP in breast cancer cells. Int J Clin Exp Med. 8:12018–12027. 2015.PubMed/NCBI | |
|
Zhang S, Liu Z, Wu L and Wang Y: MiR-361 targets Yes-associated protein (YAP) mRNA to suppress cell proliferation in lung cancer. Biochem Biophys Res Commun. 492:468–473. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Lo Sardo F, Forcato M, Sacconi A, Capaci V, Zanconato F, Di Agostino S, Del Sal G, Pandolfi PP, Strano S, Bicciato S, et al: MCM7 and its hosted miR-25, 93 and 106b cluster elicit YAP/TAZ oncogenic activity in lung cancer. Carcinogenesis. 38:64–75. 2017. View Article : Google Scholar : PubMed/NCBI |
